Loading
Life sciences · Journal article
Langenbeck S Archives of Surgery · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Metabolic and bariatric surgery (MBS) is an effective treatment for patients with obesity and type 2 diabetes (T2D). Preoperative T2D severity may influence perioperative safety and T2D outcomes after MBS. Methods A retrospective analysis of a single-center database of adults with T2D who underwent MBS between January 2017-May 2024. Patients were divided into controlled and uncontrolled T2D groups according to preoperative T2D status. Baseline characteristics, perioperative complications, and mid-term outcomes were analyzed and compared. Results Among 203 patients included, 124 had controlled T2D and 79 had uncontrolled T2D. Patients with uncontrolled T2D were older (52.4 ± 10.2 vs. 48.1 ± 11.5 years, p = 0.03) and had a worse baseline metabolic profile, including higher HbA1c levels (8.25 ± 0.93% vs. 6.09 ± 0.45%, p < 0.001), higher fasting glucose levels (155.8 ± 39.9 vs. 121.0 ± 24.5 mg/dL, p < 0.001), and greater insulin use (35.4% vs. 5.6%, p < 0.001). Overall, 90-day complications were insignificantly higher in the uncontrolled group (13.9% vs. 7.3%, p = 0.053). At a mean follow-up of 41.4 ± 28.0 months, total weight loss was comparable (28.02%±12.51 vs. 27.28%±11.03, p = 0.71). Patients with uncontrolled T2D had higher antidiabetic medication use (44.5% vs. 19.4%, p < 0.001), higher insulin use (8.3% vs. 1.2%, p = 0.034), and higher HbA1c levels (6.20 ± 0.92% vs. 5.43 ± 0.52%, p < 0.001). T2D remission was higher among patients with controlled T2D (79.5% vs. 51.8%, p < 0.001). Conclusion Patients with controlled T2D before MBS achieved higher remission rates than patients with uncontrolled T2D, despite comparable weight loss outcomes. Interestingly, patients with uncontrolled T2D still experienced meaningful glycemic improvement and reduced medication burden, supporting the benefit of MBS in this high-risk group.